faculty photo

Michael Gelfand, MD, PhD

Associate Professor of Clinical Neurology
Department: Neurology

Contact information
Department of Neurology
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104-4283
Office: 215-662-3606
Education:
BS & MS (Molecular Biophysics and Biochemistry )
Yale University, 2001.
PhD (Neuroscience)
Rockefeller University, 2009.
MD (Doctor of Medicine)
Weill Cornell Medical College, 2010.
Post-Graduate Training
Intern in Medicine, St. Luke`s-Roosevelt Hospital Center, New York, NY, 2010-2011.
Resident in Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2011-2014.
Fellow in Epilepsy/Neurophysiology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2014-2015.
Certifications
Neurology (American Board of Psychiatry and Neurology(ABPN)), 2014.
Epilepsy (American Board of Psychiatry and Neurology(ABPN)), 2016.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Epilepsy, EEG, Clinical Neurophysiology, Epilepsy Surgery, Antiepileptic Drugs, Electrocorticography

Description of Research Expertise

Clinical Trials

Selected Publications

Hina Dave, MD - UT Southwestern Medical Center; Jacqueline French, MD - NYU Comprehensive Epilepsy Center; Hamada Hamid Altalib, DO, MPH, FAES - Yale University; Heidi Henninger, MD - Maine Medical Center; Roger Porter, MD, ScD - Perelman School of Medicine, University of Pennsylvania; Michael Gelfand, MD, PhD - University of Pennsylvania; Melinda Martin, PhD - UCB Pharma, Smyrna; Prashant Dongre, MD - UCB Pharma, Smyrna; Sami Elmoufti, MS - UCB Pharma, Raleigh; Anne-Liv Schulz, MD - UCB Pharma, Monheim am Rhein; Michael Sperling, MD - Thomas Jefferson University: Real-World Study of Brivaracetam in the United States. American Epilepsy Society December 2021.

Sen A, Verner R, Valeriano JP, Lee R, Zafar M, Thomas R, Kotulska K, Jespers E, Dibué M, Kwan P; CORE-VNS Registry Group.: Vagus nerve stimulation therapy in people with drug-resistant epilepsy (CORE-VNS): rationale and design of a real-world post-market comprehensive outcomes registry. BMJ Neurol Open 3: e000218, Dec 2021.

Syndi Seinfeld, DO - Joe DiMaggio Children’s Hospital; Carla Buan - Aquestive Therapeutics; Michael Gelfand - University of Pennsylvania; Allen Heller - Pharma Study Design, LLC; Ayman Kafal - Aquestive Therapeutics; gary Slatko - Aquestive Therapeutics: Diazepam Buccal Film (DBF): Final Results from a Phase 3, Open-Label, Safety and Tolerability Study of Chronic Intermittent Use in Pediatric, Adolescent and Adult Subjects with Epilepsy. American Epilepsy Society December 2021.

Manisha Holmes; aaron smith; Dennis Dlugos; Michael Gelfand; tricia Ting; Orrin Devinsky; Jacqueline French: Differentiating Generalized Epilepsy vs Focal Epilepsy with Secondary Bilateral Synchrony in Newly Diagnosed Patients. American Epilepsy Society December 2021.

Heidi Henninger, MD - Maine Medical Center; Michael Sperling, MD – Thomas Jefferson University; Hamada Hamid Altalib, DO, MPH – Yale University; Hina Dave, MD – University of Texas Southwestern Medical Center; Michael Gelfand, MD, PhD – University of Pennsylvania; Roger Porter, MD - University of Pennsylvania; Melinda Martin, PhD – UCB Pharma, Smyrna; Sami Elmoufti, MS – UCB Pharma, Raleigh; Anne-Liv Schulz, MD – UCB Pharma, Monheim am Rhein; Prashant Dongre, MD – UCB Pharma, Smyrna; Jacqueline French, MD – NYU Comprehensive Epilepsy Center: Effectiveness and Tolerability of Brivaracetam by Reason for Initiation in Adults with Focal Seizures: Post-hoc Analysis of a Real-world, US Study. American Epilepsy Society December 2021.

Hamada Hamid Altalib, DO, MPH - Yale University; Jacqueline French, MD – New York University Comprehensive Epilepsy Center; Michael Sperling, MD – Thomas Jefferson University; Heidi Henninger, MD – Maine Medical Partners Neurology; Hina Dave, MD – University of Texas Southwestern Medical Center; Michael Gelfand, MD, PhD – University of Pennsylvania; Anne-Liv Schulz, MD – UCB Pharma, Monheim am Rhein; Sami Elmoufti, MS – UCB Pharma, Raleigh; Prashant Dongre, MD – UCB Pharma, Smyrna; Melinda Martin, PhD – UCB Pharma, Smyrna: Patient-reported Outcomes in Mood, Fatigue, Sleep Disturbance, and Disability While on Brivaracetam Treatment: A Prospective Observational Study. American Epilepsy Society December 2021.

Jacqueline A French 1, Andrew J Cole 1, Edward Faught 1, William H Theodore 1, Annamaria Vezzani 1, Kore Liow 1, Jonathan J Halford 1, Robert Armstrong 1, Jerzy P Szaflarski 1, Sarah Hubbard 1, Jagdish Patel 1, Kun Chen 1, Wei Feng 1, Marco Rizzo 2, Jacob Elkins 1, Gabrielle Knafler 1, Kimberly A Parkerson 1, OPUS Study Group [As member of OPUS Study Group]: Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study. Neurology 97(18): e1757-1767, Nov 2021.

Alisha Jamil, Noah Levinson, Michael Gelfand, Chloe E Hill, Pouya Khankhanian, Kathryn A Davis: Efficacy and Tolerability of Clobazam in Adults With Drug-Refractory Epilepsy. Neurol Clin Pract 11(5): e669-676, Oct 2021.

Acton EK, Khazaal O, Willis AW, Gelfand MA, Hennessy S, Selim MH, Kasner SE.: Statins for the Prevention of Post-Stroke Seizure and Epilepsy Development: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis 30: 106024, Aug 2021.

Tatum WO, Hirsch LJ, Gelfand MA, Acton EK, LaFrance WC, Duckrow RB, Chen D, Blum AS, Hixson J, Drazkowski J, Benbadis S, Cascino GD; OSmartViE Collaborators.: Video quality using outpatient smartphone videos in epilepsy: Results from the OSmartViE study. Eur J Neurol. 28(5): 1453-1462, May 2021 Notes: doi: 10.1111/ene.14744. Epub 2021 Feb 11.

back to top
Last updated: 07/21/2022
The Trustees of the University of Pennsylvania